STOCK TITAN

Ikarian Capital reports 4.9% Alpha Cognition (ACOG) stake via 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Alpha Cognition Inc. shareholder Ikarian Capital, LLC reported beneficial ownership of 1,056,259 common shares, equal to 4.9% of Alpha Cognition’s outstanding stock. The stake is held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.

The 4.9% figure is based on 21,742,104 common shares outstanding as of November 13, 2025. The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alpha Cognition.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent common shares, no par value per share ("Common Shares") of Alpha Cognition Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 21,742,104 Common Shares of the Issuer outstanding as of November 13, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent Common Shares of the Issuer held by the Fund and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 21,742,104 Common Shares of the Issuer outstanding as of November 13, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G



Ikarian Capital, LLC
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:02/17/2026
Neil Shahrestani
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:02/17/2026
Exhibit Information

A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on February 14, 2025 by the Reporting Persons with the SEC.

FAQ

What percentage of Alpha Cognition (ACOG) does Ikarian Capital report owning?

Ikarian Capital reports beneficial ownership of 4.9% of Alpha Cognition’s common shares. This percentage is based on 21,742,104 common shares outstanding as of November 13, 2025, as disclosed in Alpha Cognition’s Form 10-Q for the quarter ended September 30, 2025.

How many Alpha Cognition (ACOG) shares are beneficially owned according to this Schedule 13G/A?

The filing reports beneficial ownership of 1,056,259 Alpha Cognition common shares. These shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts for which Ikarian Capital, LLC acts as investment manager or sub-adviser with investment discretion.

Who are the reporting persons in this Alpha Cognition (ACOG) Schedule 13G/A amendment?

The reporting persons are Ikarian Capital, LLC and Neil Shahrestani. Ikarian Capital is an investment adviser and investment manager for the fund and managed accounts, and Shahrestani indirectly controls Ikarian Capital and may be deemed to indirectly beneficially own the reported securities.

How is the 4.9% Alpha Cognition (ACOG) ownership stake calculated in the filing?

The 4.9% ownership is calculated using 21,742,104 common shares outstanding as of November 13, 2025. That outstanding share count comes from Alpha Cognition’s Form 10-Q for the quarter ended September 30, 2025, which was filed with the SEC on November 13, 2025.

Does Ikarian Capital seek to influence control of Alpha Cognition (ACOG) with this stake?

The reporting persons certify the securities were acquired and are held in the ordinary course of business. They state the shares were not acquired and are not held for changing or influencing control of Alpha Cognition, nor in connection with any transaction having that purpose or effect.

In whose name are the Alpha Cognition (ACOG) shares actually held?

The reported Alpha Cognition common shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital, LLC has investment discretion over the fund and these accounts, and thus may be deemed to beneficially own the securities reported in this Schedule 13G/A.
Alpha Cognition

NASDAQ:ACOG

ACOG Rankings

ACOG Latest News

ACOG Latest SEC Filings

ACOG Stock Data

126.10M
19.26M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
Canada
VANCOUVER